![](https://ml.globenewswire.com/media/OTVlNTE0MzctMTliZS00MGU1LWIwYjAtNjg1MmJjMjA3ZjM4LTEyNzQ0MjE=/tiny/Io-Therapeutics-Inc-.png)
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development ...
SPRING, Texas, July 16, 2024 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use …